EP1846037A4 - Methods of treating various conditions by administration of sustained release l-arginine - Google Patents

Methods of treating various conditions by administration of sustained release l-arginine

Info

Publication number
EP1846037A4
EP1846037A4 EP06733787A EP06733787A EP1846037A4 EP 1846037 A4 EP1846037 A4 EP 1846037A4 EP 06733787 A EP06733787 A EP 06733787A EP 06733787 A EP06733787 A EP 06733787A EP 1846037 A4 EP1846037 A4 EP 1846037A4
Authority
EP
European Patent Office
Prior art keywords
arginine
administration
methods
sustained release
various conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06733787A
Other languages
German (de)
French (fr)
Other versions
EP1846037A1 (en
Inventor
Eyal S Ron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palmetto Pharmaceuticals LLC
Original Assignee
Palmetto Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/042,017 external-priority patent/US20050288372A1/en
Priority claimed from US11/107,395 external-priority patent/US20050288373A1/en
Application filed by Palmetto Pharmaceuticals LLC filed Critical Palmetto Pharmaceuticals LLC
Publication of EP1846037A1 publication Critical patent/EP1846037A1/en
Publication of EP1846037A4 publication Critical patent/EP1846037A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
    • A23L19/01—Instant products; Powders; Flakes; Granules
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/117—Flakes or other shapes of ready-to-eat type; Semi-finished or partly-finished products therefor
    • A23L7/126—Snacks or the like obtained by binding, shaping or compacting together cereal grains or cereal pieces, e.g. cereal bars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP06733787A 2005-01-24 2006-01-23 Methods of treating various conditions by administration of sustained release l-arginine Withdrawn EP1846037A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/042,017 US20050288372A1 (en) 2003-09-29 2005-01-24 Methods of treating various conditions by administration of sustained released L-Arginine
US11/107,395 US20050288373A1 (en) 2002-10-24 2005-04-14 Methods of treating various conditions by administration of sustained release L-arginine
PCT/US2006/002127 WO2006081147A1 (en) 2005-01-24 2006-01-23 Methods of treating various conditions by administration of sustained release l-arginine

Publications (2)

Publication Number Publication Date
EP1846037A1 EP1846037A1 (en) 2007-10-24
EP1846037A4 true EP1846037A4 (en) 2008-03-12

Family

ID=56290773

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06733787A Withdrawn EP1846037A4 (en) 2005-01-24 2006-01-23 Methods of treating various conditions by administration of sustained release l-arginine

Country Status (4)

Country Link
EP (1) EP1846037A4 (en)
AU (1) AU2006208293A1 (en)
CA (1) CA2595651A1 (en)
WO (1) WO2006081147A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2809638C1 (en) * 2023-05-24 2023-12-14 Федеральное государственное бюджетное учреждение науки Федеральный исследовательский центр питания, биотехнологии и безопасности пищи (ФГБУН "ФИЦ питания и биотехнологии") Product specialized with arginine

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101271538B1 (en) 2011-06-24 2013-06-05 (주)이뮤노텍 Composition for prevention and improvement of obesity comprised of organic acid, L-carnitine, L-arginine and nicotinamide

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0441119A2 (en) * 1990-01-09 1991-08-14 Richard D. Levere The use of L-Arginine in the treatment of hypertension and other vascular disorders
WO2000045651A1 (en) * 1999-02-02 2000-08-10 Novartis Nutrition Ag Oral arginine and insulin secretion
US6475530B1 (en) * 2000-05-31 2002-11-05 Eric H. Kuhrts Methods and compositions for producing weight loss
US20030078269A1 (en) * 2001-03-22 2003-04-24 Chronorx, Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
WO2004037203A2 (en) * 2002-10-24 2004-05-06 Enos Pharmaceuticals, Inc. Sustained release l-arginine formulations and methods of manufacture and use
US20040180077A1 (en) * 2003-03-05 2004-09-16 Riker Donald K. Rapidly dissolving edible strips for treating obesity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920098A (en) * 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
SE9600070D0 (en) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
JP2004501121A (en) * 2000-06-09 2004-01-15 エルイーケー　ファーマシューティカルズ　ディー．ディー． Compound having stable pharmaceutical effect and pharmaceutical preparation containing the same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0441119A2 (en) * 1990-01-09 1991-08-14 Richard D. Levere The use of L-Arginine in the treatment of hypertension and other vascular disorders
WO2000045651A1 (en) * 1999-02-02 2000-08-10 Novartis Nutrition Ag Oral arginine and insulin secretion
US6475530B1 (en) * 2000-05-31 2002-11-05 Eric H. Kuhrts Methods and compositions for producing weight loss
US20030078269A1 (en) * 2001-03-22 2003-04-24 Chronorx, Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
WO2004037203A2 (en) * 2002-10-24 2004-05-06 Enos Pharmaceuticals, Inc. Sustained release l-arginine formulations and methods of manufacture and use
US20040180077A1 (en) * 2003-03-05 2004-09-16 Riker Donald K. Rapidly dissolving edible strips for treating obesity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2006081147A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2809638C1 (en) * 2023-05-24 2023-12-14 Федеральное государственное бюджетное учреждение науки Федеральный исследовательский центр питания, биотехнологии и безопасности пищи (ФГБУН "ФИЦ питания и биотехнологии") Product specialized with arginine

Also Published As

Publication number Publication date
EP1846037A1 (en) 2007-10-24
AU2006208293A1 (en) 2006-08-03
CA2595651A1 (en) 2006-08-03
WO2006081147A1 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
HK1199874A1 (en) Spiro-oxindole compounds and their uses as therapeutic agents
IL216401A0 (en) Sustained release of antinfectives
IL186615A0 (en) Spiroheterocylic compounds and their uses as therapeutic agents
EP2068864A4 (en) Therapeutic uses of urolithins
EP1962961A4 (en) Demibodies: dimerisation-activated therapeutic agents
ZA200808178B (en) Imidazolothiazole compounds for the treatment of disease
GB0609492D0 (en) Therapeutic agents
GB0608928D0 (en) Therapeutic agents
IL211835A0 (en) Therapeutic uses of inhibitors of rtp801
SI2137141T1 (en) Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents
PL2225238T3 (en) Derivatives of 6,7-dihydro-5h-imidazoý1,2- ¨imidazole-3- carboxylic acid amides
SI2229369T1 (en) 6,7-dialkoxy-quinazoline derivatives useful for treatment of cancer-related disorders
EP1968603A4 (en) Therapeutic amine-arylsulfonamide conjugate compounds
EP2114415A4 (en) Methods and compounds for the targeted delivery of agents to bone for interaction therewith
EP1939170A4 (en) Process for the preparation of gabapentin hydrochloride
GB0620818D0 (en) Therapeutic agents
GB0620059D0 (en) Therapeutic agents
GB0609676D0 (en) Therapeutic agents
EP2157089A4 (en) The therapeutic uses of imidazol-5-carboxylic acid derivatives
EP1846037A4 (en) Methods of treating various conditions by administration of sustained release l-arginine
GB0501129D0 (en) Method of treatment by administration of RNA
ZA200805701B (en) Salts of styphnic acid
GB0623740D0 (en) Treatment of disease
GB0622195D0 (en) Therapeutic agents
EP2056811A4 (en) Modafinil-based treatment for premature ejaculation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070824

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PALMETTO PHARMACEUTICALS, LLC

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/22 20060101ALI20080131BHEP

Ipc: A61P 3/06 20060101ALI20080131BHEP

Ipc: A61P 3/10 20060101ALI20080131BHEP

Ipc: A61P 11/06 20060101ALI20080131BHEP

Ipc: A61P 3/04 20060101ALI20080131BHEP

Ipc: A61K 31/198 20060101ALI20080131BHEP

Ipc: A61K 9/52 20060101ALI20080131BHEP

Ipc: A61K 47/32 20060101AFI20060809BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20080207

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20080724

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081204